JK-1201I

· JenKem Technology Co., Ltd.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for JK-1201I, covering 2024-09-03 to 2024-09-19. Get the full timeline:

Most recent: Clinical Trial Update: JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM) [Phase 2]

See pricing